Search | Global Index Medicus

ABSTRACT

El descubrimiento de los genes BRCA1 y BRCA2 ha llevado a la introducción de pruebas genéticas cada vez más sofisticadas para medir el riesgo de cáncer de mama de origen hereditario, entre otras cosas. En el presente artículo exploramos los criterios a seguir para realizar pruebas para estos genes, así como las implicaciones en el tratamiento para los pacientes en caso de identificarlos.

The discovery of genes BRCA1 and BRCA2 has led to the introduction of genetic tests more complex every time for the evaluation ofthehereditarycancerrisk,amongothers.In the present paper we explore the criteria to decide when to run the testing for the genes, as well as the implications for the treatment of patients who are identified with them.

Subject(s)

Female , Humans , Breast Neoplasms/genetics , Genes, BRCA1 , Genetic Testing , Neoplastic Syndromes, Hereditary/genetics , Breast Neoplasms/classification , Breast Neoplasms/epidemiology , Breast Neoplasms/pathology , Breast Neoplasms/prevention & control , Comorbidity , Estrogen Receptor Modulators/therapeutic use , Estrogens/adverse effects , Ethnicity/genetics , Family Health , Forecasting , Founder Effect , Gene Frequency , Genetic Predisposition to Disease/genetics , Mastectomy , Mexico/epidemiology , Neoplasms, Hormone-Dependent/epidemiology , Neoplasms, Hormone-Dependent/genetics , Neoplasms, Hormone-Dependent/pathology , Neoplasms, Multiple Primary/epidemiology , Neoplasms, Multiple Primary/genetics , Neoplastic Syndromes, Hereditary/epidemiology , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/genetics , Ovarian Neoplasms/prevention & control , Reproductive History , Risk

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL